This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2023, the FDA approved six vaccines, including 2 for respiratory syncytial virus (RSV), and the first vaccine to prevent the mosquito-borne virus chikungunya.
Keep your pharmacy vaccine-ready for your youngest patients with the most current influenza vaccination information from the American Academy of Pediatrics.
Innovation in the vaccine area continues. In 2023, the FDA approved six vaccines, including several important firsts. But they face a difficult landscape where federal policies dictate coverage.
2023 was a year packed with advancements in the vaccine, biosimilar, and therapeutic spaces. Explore the approvals that emerged in 2023 from these advancements in our slideshow series outlining the impact of each on the general health care landscape.
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. Shadowed by the successes of other therapies, the field of cancer vaccines was “seemingly dying,” Sullivan said. Continue to STAT+ to read the full story…
Although I have practiced in the area of infectious diseases pharmacy for quite a while now, measles has not been of much clinical relevance to me beyond MMR for routine vaccination. Vaccination is the best way to prevent measles This is an obvious one, but necessary to state right out the gate. MMR is given in 2 doses.
Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2023 flu season are quadrivalent.
Is your pharmacy leaving revenue on the table by not having a year round vaccine program? Pacience Edwards, PharmD, answers that question and more during the July 2023 Total Pharmacy Solution Summit.
CDC to weigh who should get updated COVID-19 vaccines after FDA approval, Novavax says its updated COVID-19 vaccine is ready for distribution, and Walgreens partners with Pearl Health to expand primary care services.
5 to "variant of interest," Amazon-owned One Medical expands across US, and health officials urge vaccination before the coming fall season. WHO upgrades EG.5
CDC survey finds Interventions are needed to facilitate the implementation of updated pneumococcal vaccine recommendations, HHS proposes a new rule the seeks to prohibit discrimination based on disabilities, and a new report says there is a need for improved access to pediatric subspecialty care.
Cue Health gets FDA’s first de novo approval for at-home COVID-19 test, Novavax says its new vaccine will fight new variants and HHS creates new cert standards for peer support workers.
Researchers explored the efficacy of Pfizer-BioNTech’s updated COVID-19 vaccine for the 2023-2024 period and its efficacy in improving various patient outcomes.
The CDC emphasized the need for protein-based vaccine options in endorsing a vote by the Advisory Committee on Immunization Practices for the universal recommendation of the 2023-2024 monovalent, XBB containing COVID-19 vaccines.
Study results outlined in a poster at ASHP Midyear 2023 revealed that virtual delivery education programs could contribute to a more inclusive and accessible health care information landscape for Black older adults.
The FDA approved a licensure request for Fluzone High-Dose Quadrivalent, Flublok Quadrivalent, and Fluzone Quadrivalent for use in the upcoming 2022-2023 flu season, providing influenza vaccination for adults 65 years of age and older.
For community pharmacists, cooler temperatures, school buses on the roads and Friday night football are not just signs of a changing season – they are indicators that patients will soon be seeking vaccinations for the 2023-2024 respiratory illness season.
The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.
Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. billion) for 2023, coming up short of expectations. Sales came to 1.5 billion euros ($1.6
has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. It also has potential to develop vaccines for other respiratory diseases, such as flu and respiratory syncytial virus. Moderna, Inc.
Makers of RSV vaccines for older adults saw their plans to try to expand usage hit a significant hurdle on Wednesday, when an expert committee that advises the Centers for Disease Control and Prevention on vaccines recommended changes that will likely see fewer older adults qualify for insurance coverage for these products.
Stefan Merlo, Vice President, Commercial Development, CSL Seqirus discusses how COVID-19 has evolved the discussion of vaccines and the long-term concerns stemming from flu vaccine fatigue.
LONDON — Two pioneers of mRNA research — the technology that helped the world tame the virus behind the Covid-19 pandemic — won the 2023 Nobel Prize in medicine or physiology on Monday.
After having missed multiple deadlines for ending polio transmission, the Global Polio Eradication Initiative had set 2023 as the year when both wild polio viruses would finally be snuffed out and so-called vaccine-derived viruses would also be stopped, putting an end to a family of viruses that have paralyzed children for centuries.
Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition. Moderna’s Spikevax XBB.1.5-adapted
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
469 
Let's personalize your content